|
Immunotherapy
Citations 21-30 of 577 total displayed.
|
Past content
(since Jun 2000):
|
Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
- Roberto Stasi, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Margherita M. Trawinska, Nichola Cooper, and Sergio Amadori
Blood 2007; 110: 2924-2930.
[Abstract]
[Full text]
[PDF]
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies
- Ingrid G. Schuster, Dirk H. Busch, Elfriede Eppinger, Elisabeth Kremmer, Slavoljub Milosevic, Christine Hennard, Christina Kuttler, Joachim W. Ellwart, Bernhard Frankenberger, Elfriede Nößner, Christoph Salat, Christian Bogner, Arndt Borkhardt, Hans-Jochem Kolb, and Angela M. Krackhardt
Blood 2007; 110: 2931-2939.
[Abstract]
[Full text]
[PDF]
The immunogenicity of Bcr-Abl–expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl–regulated antigens
- Florian Scheich, Justus Duyster, Christian Peschel, and Helga Bernhard
Blood 2007; 110: 2556-2560.
[Abstract]
[Full text]
[PDF]
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc RIIIa-158 V/V and V/F polymorphism
- Evdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, Zachary R. Hunter, Bryan T. Ciccarelli, Sigitas Verselis, Michael Modica, Yang Cao, Robert J. Manning, Xavier Leleu, Elizabeth A. Dimmock, Alexandros Kortsaris, Constantine Mitsiades, Kenneth C. Anderson, Edward A. Fox, and Steven P. Treon
Blood 2007; 110: 2561-2564.
[Abstract]
[Full text]
[PDF]
Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
- Barbara Savoldo, Cliona M. Rooney, Antonio Di Stasi, Hinrich Abken, Andreas Hombach, Aaron E. Foster, Lan Zhang, Helen E. Heslop, Malcolm K. Brenner, and Gianpietro Dotti
Blood 2007; 110: 2620-2630.
[Abstract]
[Full text]
[PDF]
Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan
- Masanao Teramura, Akiro Kimura, Satsuki Iwase, Yuji Yonemura, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, and Hideaki Mizoguchi
Blood 2007; 110: 1756-1761.
[Abstract]
[Full text]
[PDF]
Graft-versus-leukemia effects associated with detectable Wilms tumor-1–specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia
- Katayoun Rezvani, Agnes S. M. Yong, Bipin N. Savani, Stephan Mielke, Keyvan Keyvanfar, Emma Gostick, David A. Price, Daniel C. Douek, and A. John Barrett
Blood 2007; 110: 1924-1932.
[Abstract]
[Full text]
[PDF]
An NKT-mediated autologous vaccine generates CD4 T-cell–dependent potent antilymphoma immunity
- Yeonseok Chung, Hong Qin, Chang-Yuil Kang, Sanghee Kim, Larry W. Kwak, and Chen Dong
Blood 2007; 110: 2013-2019.
[Abstract]
[Full text]
[PDF]
Targeted cancer therapy with a novel low-dose rate  -emitting radioimmunoconjugate
- Jostein Dahle, Jørgen Borrebæk, Thora J. Jonasdottir, Anne Kristine Hjelmerud, Katrine B. Melhus, Øyvind S. Bruland, Oliver W. Press, and Roy H. Larsen
Blood 2007; 110: 2049-2056.
[Abstract]
[Full text]
[PDF]
The unexpected effect of cyclosporin A on CD56+CD16– and CD56+CD16+ natural killer cell subpopulations
- Hongbo Wang, Bartosz Grzywacz, David Sukovich, Valarie McCullar, Qing Cao, Alisa B. Lee, Bruce R. Blazar, David N. Cornfield, Jeffrey S. Miller, and Michael R. Verneris
Blood 2007; 110: 1530-1539.
[Abstract]
[Full text]
[PDF]
|
|
